OBJECTIVE: To probe into the clinical efficacy of oseltamivir phosphate capsules combined with Lianhua Qingwen granules in the treatment of influenza A H1 N1. METHODS: Totally 186 patients with influenza A H1 N1 admitted into the 305 Hospital of People’s Liberation Army from Oct. 2018 to Feb. 2020 were extracted to be divided into the combined treatment group（ Oseltamivir phosphate capsules combined with Lianhua Qingwen granules

n = 62）

oseltamivir group（ Oseltamivir phosphate capsules

n = 62） and Lianhua Qingwen group（ Lianhua Qingwen granules

n = 62） via random number table. The clinical efficacy

symptom relief time

negative rate of influenza A virus nucleic acid and adverse drug reactions were compared among three groups. RESULTS: The relief time of fever

systemic symptoms

nasal symptoms

sore throat and cough/expectotum in the combined treatment group was shorter than that in the oseltamivir group and Lianhua Qingwen group

with statistically significant difference（ P<0. 05）. The clinical efficacy in the combined treatment group were significantly higher than those in the oseltamivir group and Lianhua Qingwen group

with statistically significant difference（ P < 0. 05）. The negative rate of influenza A virus nucleic acid in the combined treatment group was higher than that in the oseltamivir group

and was significantly higher than that in the Lianhua Qingwen group（ with statistically significant difference

P < 0. 05）. The incidence of adverse drug reactions in the combined treatment group

oseltamivir group and Lianhua Qingwen group were respectively6. 5%（ 4/62）

6. 5%（ 4/62） and 4. 8%（ 3/62）

the incidence of adverse drug reactions in the combined treatment group was lower

and there was no significant difference among three groups（ P >0. 05）. CONCLUSIONS:Oseltamivir phosphate capsules combined with Lianhua Qingwen granules in the treatment of influenza A H1 N1 can effectively improve the efficacy and symptoms

and increase the negative rate of influenza A virus nucleic acid with lower incidence of adverse drug reactions.